Improved sleep continuity and increased slow wave sleep and REM latency during ziprasidone treatment: a randomized, controlled, crossover trial of 12 healthy male subjects.

doi:10.4088/JCP.V66N0805

Paper

Improved sleep continuity and increased slow wave sleep and REM latency during ziprasidone treatment: a randomized, controlled, crossover trial of 12 healthy male subjects.

Published Aug 15, 2005 · S. Cohrs, A. Meier, A. Neumann

The Journal of clinical psychiatry

Q1 SJR score

57

Citations

1

Influential Citations

Full textSemantic Scholar

Abstract

OBJECTIVE Ziprasidone, an atypical antipsychotic, is a potent dopamine (D(2)) and serotonin (5-HT(2A/C)) receptor blocker, has agonistic properties at the 5-HT(1A) receptor, and blocks serotonin and norepinephrine reuptake. These transmitter systems are closely related to the regulation of sleep. METHOD The aim of this double-blind, placebo-controlled, randomized, crossover study was to investigate the effects of ziprasidone on polysomnographic sleep structure and subjective sleep quality. Twelve healthy male subjects were randomly assigned to receive ziprasidone 40 mg or placebo for 2 sessions each composed of 2 consecutive nights (night 1, standard sleep conditions; night 2, acoustic stress) 5 days apart. Treatment was administered orally 2 hours before bedtime. The study was conducted from April 2004 to July 2004. RESULTS Ziprasidone significantly increased total sleep time, sleep efficiency, percentage of sleep stage 2, and slow wave sleep; decreased the number of awakenings; and significantly affected tonic and phasic REM sleep parameters, i.e., it decreased percentage of REM and REM density and profoundly increased REM latency. CONCLUSION Ziprasidone's effects on the sleep profile are somehow opposite to what is known about sleep of depressed patients (e.g., disturbances of sleep continuity, a reduciton of slow wave sleep, and a disinhibition of REM sleep). Its REM sleep-suppressing properties resemble those of most, although not all, antidepressants and may be clinically relevant. The drug also demonstrates sleep-consolidating properties under both standard routine and acoustic stress conditions. These effects are most likely related to ziprasidone's 5-HT(2C) antagonism, 5-HT(1A) agonism, and serotonin and norepinephrine reuptake inhibition.

RCT

Study Snapshot

Ziprasidone improves sleep continuity, slow wave sleep, and REM latency, while decreasing REM sleep and demonstrating sleep-consolidating properties under both routine and acoustic stress conditions.

PopulationOlder adults (50-71 years)

Sample size24

MethodsObservational

OutcomesBody Mass Index projections

ResultsSocial networks mitigate obesity in older groups.

Sign up to use Study Snapshot

Consensus is limited without an account. Create an account or sign in to get more searches and use the Study Snapshot.

Create an account

Paper

Improved sleep continuity and increased slow wave sleep and REM latency during ziprasidone treatment: a randomized, controlled, crossover trial of 12 healthy male subjects.

Sign up to use Study Snapshot

References

Citations

Mechanisms Underlying the Action of Ziziphi Spinosae Semen in the Treatment of Insomnia: A Study Involving Network Pharmacology and Experimental Validation

ZSS extract effectively treats insomnia by regulating serotonergic and GABAergic pathways, providing a potential basis for developing innovative insomnia treatments.

Pharmacological Treatment for Long-Term Patients with Schizophrenia and Its Effects on Sleep in Daily Clinical Practice: A Pilot Study

Pharmacological treatment for long-term schizophrenia patients is variable and insufficiently addresses sleep problems, with no gender differences in drug use.

In-Home Sleep Recordings in Military Veterans With Posttraumatic Stress Disorder Reveal Less REM and Deep Sleep <1 Hz

Veterans with PTSD tend to spend less time in REM and deep sleep stages, with medication use contributing to decreased sleep efficiency.

The effects of second generation antipsychotic drugs on sleep variables in healthy subjects and patients with schizophrenia.

Second-generation antipsychotics like clozapine, olanzapine, and paliperidone may improve insomnia in patients with schizophrenia by reducing sleep latency and increasing total sleep time and sleep efficiency.

Antipsychotics as antidepressants

Antipsychotics can be effective for depression at subantipsychotic doses, with unique antidepressant effects observed in quetiapine, aripiprazole, and possibly lurasidone.

Ziprasidone as a Potential Abortive Therapy for Status Migrainosus

Ziprasidone may be a safe and effective abortive medication for treating status migrainosus, with a 12% 30-day readmission rate for migraine headaches.

The sleep effects of lurasidone: a placebo‐controlled cross‐over study using a 4‐h phase‐advance model of transient insomnia

Lurasidone, an atypical antipsychotic, does not significantly affect sleep or circadian function in a 4 hour phase-advance model of transient insomnia.

Sleep Disturbances in Schizophrenia.

Sleep disturbances in schizophrenia patients are linked to disruption of neurotransmitter systems and dysregulation of clock genes, with antipsychotic medications playing a significant role in treating these issues.